This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
Journal of Neurology Open Access 19 April 2023
-
Human in silico trials for parametric computational fluid dynamics investigation of cerebrospinal fluid drug delivery: impact of injection location, injection protocol, and physiology
Fluids and Barriers of the CNS Open Access 28 January 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pearn J . Classification of spinal muscular atrophies. Lancet 1980; 1: 919–922.
Burglen L, Lefebvre S, Clermont O, Burlet P, Viollet L, Cruaud C et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996; 32: 479–482.
Lunn MR, Wang CH . Spinal muscular atrophy. Lancet 2008; 371: 2120–2133.
ATMP Regulation. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004.
European Medicines Agency. First medicine for spinal muscular atrophy. April 2017. Availavle at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/04/news_detail_002735.jsp&mid=WC0b01ac058004d5c1.
Picchi A . The cost of Biogen’s new drug: $750000 per patient. CBS News 29 December 2016. Available at http://www.cbsnews.com/news/the-cost-of-biogens-new-drug-spinraza-750000-per-patient/.
Simoens S . Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011; 6: 42.
Nace M . FDA approves Biogen’s Spinraza (nusinersen) as first approved SMA drug for children, adults. SMA News Today 2016.
Tambuyzer E . Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010; 9: 921–929.
Morrison C . Fresh from the biotech pipeline-2016. Nat Biotechnol 2017; 35: 108–112.
Hughes-Wilson W, Palma A, Schuurman A, Simoens S . Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012; 7: 74.
Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A . A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health 2013; 16: 1163–1169.
Garber K . Big win possible for Ionis/Biogen antisense drug in muscular atrophy. Nature Biotechnol 2016; 34: 1002–1003.
Cure SMA Report, Winter 2016. Available at: http://www.curesma.org/documents/support—care-documents/2016-winter-directions.pdf.
Corey DR . Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nature Neuroscience 2017; 20: 497–499.
Biogen Press Release 2016. Available at: http://media.biogen.com/press-release/investor-relations/biogen-and-ionis-pharmaceuticals-report-nusinersen-meets-primary-en.
Ionis Pharmaceuticals 2016. Available at: http://www.prnewswire.com/news-releases/spinraza-nusinersen-approved-in-us-to-treat-broad-range-of-patients-with-spinal-muscular-atrophy-300383512.html.
SMA Europe Announcement. Available at: http://www.sma-europe.eu/news/spinraza-community-update-by-biogen-feedback-on-a-call-with-sma-europe/.
Vandenbroeck P, Raeymakers P, Wickert R, Becher K, Goossens J, Cleemput I et al. Future scenarios about drug development and drug pricing. Health Services Research (HSR) Belgian Health Care Knowledge Centre (KCE): Brussels, 2016, KCE Reports 271. Available at: https://kce.fgov.be/publication/report/future-scenarios-about-drug-development-and-drug-pricing#.WLKeSrGZOCQ.
TRIPS, Agreement on trade-related aspects of intellectual property rights, 1994. Available at: https://www.wto.org/english/docs_e/legal_e/27-trips.pdf.
Anastasaki E, Bradshaw SE, Walker A . An update on market access for advanced-therapy medicinal products in Europe. ISPOR 17th Annual European Congress. ISPOR: Amsterdam, The Netherlands, 2014.
Hanna E, Rémuzat C, Auquier P, Toumi M . Advanced therapy medicinal products: current and future perspectives. J Market Access Health Policy 2016; 4: 31036.
Lucas F . Performance-based managed entry agreements for medicines: much needed, but not feasible? Value & Outcomes Spotlight 2016; 2: 10–12.
Acknowledgements
We thank the two anonymous referees for their insightful feedback.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
SS and IH are the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL), in which Biogen participates. The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Simoens, S., Huys, I. Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations. Gene Ther 24, 539–541 (2017). https://doi.org/10.1038/gt.2017.79
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2017.79
This article is cited by
-
The potential value of disease-modifying therapy in patients with spinocerebellar ataxia type 1: an early health economic modeling study
Journal of Neurology (2023)
-
Human in silico trials for parametric computational fluid dynamics investigation of cerebrospinal fluid drug delivery: impact of injection location, injection protocol, and physiology
Fluids and Barriers of the CNS (2022)